Top Banner
Session S2 How to measure impact on Quality and Cost The Health Service Provider Perspective or A conversation on various points of view ADVANCING CLINICAL TRIALS & REGISTRIES WITHIN THE AUSTRALIAN HEALTH SYSTEM Jane Gray Executive Director HNE Local Health District Director of Partnerships, Innovation and Research Unit Peter MacIsaac Clinical Research Informatics Lead – HMRI & HNE
41

3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

May 23, 2020

Download

Documents

dariahiddleston
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

SessionS2HowtomeasureimpactonQualityandCostTheHealthServiceProviderPerspective

orAconversationonvariouspointsofview

ADVANCINGCLINICALTRIALS&REGISTRIESWITHINTHE

AUSTRALIANHEALTHSYSTEM

JaneGrayExecutiveDirectorHNELocalHealthDistrictDirectorofPartnerships,InnovationandResearchUnit

PeterMacIsaacClinicalResearchInformaticsLead– HMRI&HNE

Page 2: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

HealthServiceDeliveryPerspectiveonInvestigator-initiatedclinical‘publicgood’trials

Studiesconductedintheabsenceofcommercialinterestanddesignedtoanswerimportantclinicalquestions,providingunbiasedscientificevidencetohelpconsumers,cliniciansandpolicymakersmakedecisionsaboutwhichtreatments,testsandservicesaremosteffectiveorofferthebestvalueforthehealthcaresystem.

• Individualinvestigators• LocalResearchPrograms• ClinicalTrialNetworks• ClinicalQualityRegistries.

Page 3: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

HunterNewEnglandHealth

• AnnualBudget>$2billion• Population– 1million(approx.)• AreathesizeofEngland• 80facilities– notjusthospitals

• Mixoftertiary,generalandlocalhospitalsandhealthfacilities• PartnershipsbetweenLHD,GPs,Communityhealth,Ambulance

• Eachfacilityhaslocalmedical,nursing,alliedhealthdepartments– withvaryingdegreesoflocalautonomy

• 12Clinicalnetworks• Muchofthedecisionmakingaboutlocalmanagementincludingresearchactivityisdevolved.

Page 4: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

Whatmakeshealthservicestick?• Frameworkandpolicydriven• Budget– costsandservicesdelivered• ContextoftheAustralian“healthsystem”• Traditionalvalues:Servicequality,efficiency,researchandteaching• Guidingprinciples.- TripleAim• 4th Aim- researchengagementsupportsinnovationandchangecultureandwehopeisan“attractor”forourmajorresource– goodclinicians.

Page 5: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

ThisisthecontextwithinwhichhealthresearchsitsPrioritiesFlowFromPremiertoLocalHealthDistrict

Page 6: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are
Page 7: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

Goonlineanddownload

KeySections&performancemeasures

Page 8: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

Ministryof

Health

NSWHealthPlan(3-5years)

LocalH

ealth

Distric

t

HNEHealthStrategicPlan/s(3-5years)

HNEHealthOperationalPlan(12Months)

Network/PortfolioOperationalPlan(12Months)

Network

Portfolio

Individu

al

Service/FacilityOperationalPlan(12Months)

IndividualPerformanceDevelopmentReview(PDR)

State

Governmen

tService

Facility

StatePlan- 2021(10yearhorizon)

HNE Health Planning and Accountability Framework

90DayActionPlan

ServiceAgreement

MonthlyAccountabilityMeetings

Individuallevel

Facilitylevel

LHDlevel

Page 9: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

EachinitiativeinourOperationalPlandrillsdowntoameasurewhichflowstoindividualleaders–allofwhomhave90dayactionplans

Numberofoverweightchildren7-13

Page 10: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

“Research”performancemeasuresrelatetoresearchgovernanceeffectiveness.However,researchcanalsohelpusdeliveronotherKPIs.

Note:with23%ofNSWAboriginalpopulation,wealsovalueresearchthathelpsClosetheGap

Page 11: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

ExamplesofResearchsupportingLHDpriorities

• GoForFun- aresearchprojectfocusingonincreasingphysicalactivityinschools.Thisaddressesakeypopulationhealthstrategy–reducingchildhoodobesityandalsomeetsoneoftheKPIsunderourserviceagreement

• DiabetesAlliance- partnershipwithourlocalPrimaryHealthcareNetwork,HunterPrimaryCareLtdandCalvarytoimproveprimaryType2diabetescare– keepingcareclosetohomeandfreeingscarcetertiaryresourcesforthemostcomplex,high-needsDiabetespatients.

• +++

Page 12: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

Evidencemeetsexperience

• Framekeystepsforresearchthroughaprogram- logicframeworkNeeds– Aims– Process– Outcomes– Implementation– Impact

• Targetissuesofimportancetoendusers- upfront

ProjectRetrosight – BrunelUniversity.Wodding etalUnderstandingfactorsassociatedwiththetranslationofcardiovascularresearch..ImplementationScience2014,(:47.FAIT– HMRI.SearlesA,etal.

Page 13: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

FrameworktoAssessImpactfromTranslationalhealthresearch– FAIT

• ModifiedPayback• Definedomainsofbenefit• Determinerelevantimpactmetrics• Inclusionofprocessmetrics.

• SocialReturnonInvestment• Costbenefit- $$return– supportsanalysisofmultiplebenefits,canbeextendedtoasocietalperspective

• $benefitfor$ofcost– alignswithcorporatethinking• Canbeincorporatedintotrialsandhealthservices

research• CaseStudies

• Providecontextandrelatetoeconomicanalysis• SummarizeasScorecard

• Prospectivelyintheplanningphase• Communicationtool

Page 14: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

EngagementwithLHDs.

• Whatwouldsuccesslooklike?• StartwiththedriversoftheLHDinmind.• Becautious:modelsofchangebasedprimarilyonfinancialincentivescanhaveunintendedoutcomesashasoccurredwith“payfortraining”ofmedical,nursingandalliedhealthstudents.

• HeterogeneityinLHDsize,structureandfunctionacrossthecountry &needtothinkregionalandincludePrimaryHealthcareNetworks- achallengeforengagement– uselocalnetworks

• Registries:Creatingaglobalpushforimprovedinformationmanagementsystemswillimprovepatientcare,efficiencyandbearesourceforresearch– oncetechnologymatures

Page 15: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are
Page 16: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

Researchrelatedactivity- HNE

• Research&InnovationAdvisoryCommittee(RIAC)- CEisamember• Partnerships,InnovationandResearchUnit- ledbyJaneGray• ResearchgovernanceandHealthResearchEthics- NicoleGerrand• RegionalResearchHub– ProfessorChrisLevi• Innovationandawardsprogram• HunterMedicalResearchInstitution– ProfessorMichaelNilsson• Communityengagement- Alliance(PHN&HNE)• Datawarehouseandimprovedaccesstodataforresearch,qualityimprovementandlinemanagement.

Page 17: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

Iftimepermits– diabetescasestudy

Page 18: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

What is the Diabetes population and workforce across Hunter and New England?

• ~60,000 patients with diabetes• 7700 patients with Type 1 Diabetes• 297 GP practices• 1032 GPs

• 27,000 patients in Newcastle cluster

• 2.75FTE Endocrinologist (public)

• 0.5FTE General Physician at Mater

• 3FTE Endocrinologist (private)

• 9.6FTE Diabetes educators

• ~1000+ New referrals/year at JHH

• ~4,500 follow ups

• 30Day and 3 month KPI not being met

• 33,000patients• 1FTE endocrinologist (recently changed to VMO in Tamworth

• 12 people employed by HNE to provide diabetes education

(unknown FTE diabetes time)

Page 19: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

Poorglycaemia

Hypoandhyperglycaemic

Diabeticemergencies,IncreasedLOS

IHD,CCF,CABG,Stroke

Retinopathy,maculopathyandblindness

ChronicKidneyDiseaseandDialysis

dependence,Transplants

PeripheralNeuropathy,Peripheral

Vasculardiseaseandamputations

Pregnancycomplications

Increasedmalformationsintheoffsprings

Psychosocialconsequences

suchasdepression

Mostaspectsofdiabetescomplicationsareeitherpreventableorreduciblebyearlyoptimaltherapy.1%HbA1creductionreducesmicrovascularcomplicationby40%asperUKPDSdata

Page 20: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

• Diabetes and its complications in the top 5 (COPD, CCF, Cellulitis, UTI) that contributed to 47% of preventable admissions and took

62% of bed days nationally

• Significant variation across the nation, rural and remote regions and those with low socioeconomic regions higher rates of admission

• Hunter and New England 2413 preventable admissions related to Diabetes

Page 21: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

• No of patients completing annual care cycles with eye and feet check, recommendations

implemented

• HbA1c at least 2 times a year (Optimal <7%, >9% very poor control, >11% immediate risks of

hospitalisation)

• Annual kidney function, lipids, urine for proteinuria (ACR)

• Those with high urine ACR on ACEI/ARB medications

• Those with absolute CV risk>10% be on statin therapy to prevent MI/Stroke/PVD

• Timely treatment escalation for those who are failing (HbA1c >7%)

Page 22: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

• Sub-optimalprocess:• 12.15%diabeticpatientsdon’tevengetasingleHbA1c>12months

• 33%patientsnotscreenedfornephropathy

• 12%nocholesterolrecorded

• Sub-optimaloutcomes:• 10.5%haveHbA1c>9%

• 6.5%withdocumentedabnormalmicroalbuminuriadonotreceiveACEI/ARB

• 31.5%withcholesterol>4mmol/lnotonmedication

• Problemmaybe– cliniciansnotunderstandingthe‘bigpicture’andperformancefeedbackinadditiontoknowledgeandskillsrequiredtomanageDiabetes

0102030405060

<=7% 7-8% 8-9% 9-11% >11% Missing

%DM

PatientsinPractice

HbA1c

HbA1c 6300 pts at very high risk of immediate

complications

Wouldweaccept6300breastcancerpatients

12.5%

Page 23: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

0

10

20

30

40

50

60

<=7% 7-8% 8-9% 9-11% >11% Missing

%DM

PatientsinPractice

HbA1c

HbA1c6300 pts at very high risk of

immediate complications

Wouldweaccept6300breastcancerpatientsnotbeingoptimallytreatedinourregion?

Whydowehaveinertiatowardsdiabetes?

12.5% don’t seem to get even 1 HbA1c annually

Page 24: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

• Creationofaregionaldiabetesqualityregistry

• Specialistteamstoupskill,supportandmonitorGPstoprovidethemajorityofcare

forpatientswithType2DiabetesMellitus

• Developadistrict-wideDiabetesServicethatprovidesSpecialistsupportto GP

practicesacrossallclusterswithinHNELHDusingamixedfacetoface+telehealth

model

• Improvetimelyaccesstothosewhowouldmostbenefitfromtertiaryservices

Page 25: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are
Page 26: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

First analysis showed

• 92%neededmedicationchanges

• 65%appropriatelyreferredashighrisk,resthigheducationalvalueforGPs

• 14%ofpatientsatveryhighriskofhospitaladmissionandcomplicationsreducedto5%by6months

• Ofthe65%appropriatelyreferred75%improvedtheirdiabetescontrol

• 51%ofthepatientslostweight

• Activitylevelincreasedfrom30%(>30mins/day)to75%(>30mins/day)

• 88%ofpatientsreportedimprovedknowledge,confidenceandskillsinselfmanagement,

• 100%involvedcliniciansfeltexperiencesatisfying/verysatisfying

Page 27: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

• At6monthsinterimfollow-upacross109patientsshowedHbA1cimprovedfrom60.2 ±15.9to55.1±12.5mmol/mol (p=0.0006);weightimprovedfrom100.1±20.6to98.7±21kg(p=0.02);totalcholesterol4.5±1.2to4.4±1.2mmol/l(0=0.04);systolicBP139±19to133±17mmHg(p=0.0003).

• 100%ofinvolvedcliniciansfelttheexperiencewas"satisfyingorverysatisfying".

MultiMillion$$$drugtrial

HunterAllianceproject

0.5%HbA1creduction

• 0.5%HbA1creduction

• Weightreduction

• Cholesterolreduction

• BPreduction

• 1500follow-upsaved

• Evidencethatbenefitsflowedto

other Diabetespatientsinthe

practice

• UpskillGPsandPracticenurses

• 68GP’seligiblefor40category1

pointsfromRACGP

=

Page 28: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

• 6 monthly feedback on performances, report + NPS portal access

• Regular feedback to each practice about HbA1c levels, urine ACR, BP, Lipids, Appropriate medications, foot and eye screening

• Ability to re identify high risk patients at practice levels to improve health

• Mentoring and integration of services 0

10

20

30

40

50

60

<=7% 7-8% 8-9% 9-11% >11% Missing

%DM

PatientsinPractice

HbA1c

05101520253035404550

AlbuminuriaonACEi/ARB

HypercholesterolaemiaonStatin

%DM

PatientsinPractice

Page 29: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

• Specialiststobeallocatedgeographicalclusterstofosterpartnershipsandresponsibleformonitoringofperformance

• BenchmarkagainstHNEaverageandoptimalperformance

• Identifythoserequiringsupport,frequentreferrers

• IdentifyGPchampions

Page 30: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are
Page 31: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

Supplementaryslides:

• FAIT• HNEResearchrelatedactivity• HunterNewEnglandCentralCoastMidNorthCoastResearchHub• RICHworkshops• HunterMedicalResearchInstitute

Page 32: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

QualityofCareRegistries– somethoughts• Thereisevidenceofeffectivenessandcosteffectivenessfrominternationalstudies– butbasedinafewcountrieswhohaveinvestedheavilyinthisapproachacrossthewholehealthsystem

• Registriestendtobe“singleissuefocused”notconnectedtoeachotherandduplicateresourcesandcouldbeseentobepotentiallyfragmentingthepatientrecord.

• Largeeffortindatacollectionatthelocallevel- aretherealsoresourcesforlocalinterpretationofdataandimprovementefforts.

• Clearlyusefulfornotonlyoutcomesresearch,butalsobenchmarkingwhensufficientdataisavailabletoallowformeaningfulcomparisons.

• Issues• Lackofinformationsystemsrelatingtoclinicalcare- makingdatacollectionaburden,ratherthanby-productofclinicalcare.Canweaffordtohaveanextensivenetworkofclinicalqualityregistrieswithoutunderpinningclinicalinformationsystems?

• Registriesshouldnotbeseenasanalternativetoeffectiveoperationalclinicaldatamanagement.• Timelinessofdataandfeedback– balancingexcellenceindataqualitywithtimelinessforimprovement

• Canweaccessourowndata,oftenseemstobedifficultonceitleavesourcontrol?• Opt-inconsentmodelsfor‘registries”addcomplexityandreduceuptake.

Page 33: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

ExamplesofwhatmightinterestLHDexecutives?• Balancingthebudget

• Newtechnology- whatislowvaluecarethatcanbeimprovedorremoved?• NeedforHealthTechnologyAssessmentthatiscontextaware- localised

• Qualityofcare• Meetingaccreditationstandards• Meetingqualityofcarestandards– increasingchallenge(especiallyinfaceoflackofclinicalinformationsystems)

• Safety– preventingandrespondingtoclinicalincidents

• Planningandprioritisation– servicedeliveryandresearch• Wherecanweputourresourcesandimpactofdemographicchanges.• Aclearapproachtoprioritisation-• Engagementofhealthservicesindefiningtheproblemsthatneedtobetackled.

Page 34: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

Research– Isitmakingadifference

• FrameworktoAssessImpactfromTranslationalhealthresearch• Encourageandmeasurebothresearchtranslation&researchimpact• StepsinTranslation

• Knowledgegeneration• Sharingofknowledge• Applicationtopractice• Multidirectionalandnonsequentialprocess

• ResearchImpact

Searlesetal.Anapproachtomeasuringandencouragingresearchtranslationandresearchimpact.HealthResearchPolicyandSystems(2016)14:60,DOI10.1186/s12961-016-0131-2

Page 35: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

• Joiningthedots-programlogicmodelfortacklingaproblem

Page 36: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

FAITKeyelements• ModifiedPayback

• Definedomainsofbenefit• Determinerelevantimpactmetrics• Inclusionofprocessmetrics.

• SocialReturnonInvestment• Costbenefit- $$return– supportsanalysisofmultiplebenefits,canbeextendedtoasocietalperspective

• $benefitfor$ofcost– alignswithcorporatethinking• Canbeincorporatedintotrialsandhealthservices

research• CaseStudies

• Providecontextandrelatetoeconomicanalysis• Scorecard

• Communicationtool

Page 37: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

Researchrelatedactivity- HNE

• Research&InnovationAdvisoryCommittee(RIAC)- CEisamember• Partnerships,InnovationandResearchUnit- ledbyJaneGray• ResearchgovernanceandHealthResearchEthics- NicoleGerrand• RegionalResearchHub– ProfessorChrisLevi• Innovationandawardsprogram• HunterMedicalResearchInstitution– ProfessorMichaelNilsson• Communityengagement- Alliance(PHN&HNE)

• Diabetes– collaborativecare• AgedCare- primarycarephonesupportforRACF• EndofLifeCare• ChronicLungDisease

• Datawarehouseandimprovedaccesstodataforresearch,qualityimprovementandlinemanagement.

Page 38: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

• LocatedoncampusofHNEtertiaryreferralcentre– JohnHunter

• Fullresearchspectrum• basictoappliedscience• Widerangeofdiseases,socialdeterminantsofhealth,

healthservices• Engagementpatientcommunities,healthservices,healthpolicymakers,academicandclinicalresearchers

• Supportsresearch• Facilitiese.g.labs,MRI• Skills– epidemiology,studydesign,statistics,

informaticsandhealtheconomics• Funding(primaryandsecondary)

HunterMedicalResearchInstitute(HMRI)

Page 39: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are
Page 40: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

ResearchHub

• Leadresearchculture• 3LHDs,oneprivatehospital,&2universities

• 6RICHworkshops• 13researchissuesdeveloped• SeedfundingfromLHDandHMRI

Page 41: 3 ACTA2016 MacIssac - Australian Clinical Trials Alliance · evidence to help consumers, clinicians and policymakers make decisions about which treatments, tests and services are

Clinicalnetworksandstreams

• 10yearsinthemaking• Bringclinicalcommunitiestogether• Keyexamples:

• Cardiac- standardisationofmodelsofcare,pre-hospitalthrombolysis• Stroke- regionalstrokeunitdevelopment

• Weareexploringnetworklevelapproachestoresearch– linkingresearchtotheissuesthatmattermosttoourcommunityandlocalclinicians

• DespiteAustralia’ssomewhatfragmentedhealthsystem(Commonwealth/State,Public/Private)wehavecreatednewpartnershipsthatkeepthehealthneedsoflocalcommunitiesasthefocus

e.g.ShouldosteoporosisandfracturepreventionbedeliveredwithahospitalbasedmodeloronethatengageswithcommunityresourcessuchasPHNsandGPs?